SCHEMBL4489129

SCHEMBL4489129

CC1(C)CN(Cc2ccsc2)CCN1C(=O)c1cc2c(C(=O)C(=O)N3CCC(O)C3)c[nH]c2cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.40
PRKAB2 O43741 7/20 0.33
PRKAG1 P54619 7/20 0.33
PRKAA2 P54646 7/20 0.33
PRKAA1 Q13131 7/20 0.33
PRKAG3 Q9UGI9 7/20 0.33
PRKAG2 Q9UGJ0 7/20 0.33
PRKAB1 Q9Y478 7/20 0.33
GABRA1 P14867 4/20 0.33
GABRG2 P18507 4/20 0.33
GABRB3 P28472 4/20 0.33
GABRA3 P34903 4/20 0.33
GABRA2 P47869 4/20 0.33
GABRB2 P47870 4/20 0.33
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513233 0.90 MAPK14 (0.38) MAPK14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL4501596 0.87 MAPK14 (0.39) MAPK14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL4506931 0.85 LMNA (0.31)
SCHEMBL4489133 0.82 MAPK14 (0.42) MAPK14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL13936173 0.82 MAPK14 (0.42) MAPK14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL4500410 0.77 POLB (0.39) MAPK14PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL4493295 0.76 MAPK14 (0.42) MAPK14
SCHEMBL4512801 0.74 MAPK14 (0.53) MAPK14HDAC1HDAC6
SCHEMBL4512803 0.74 MAPK14 (0.53) MAPK14HDAC1HDAC6
SCHEMBL4513249 0.74 ALOX5 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488744-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2009-02-10 US disclosed
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS, INC. (US) 2007-10-04 US disclosed
US-7220763-B2 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. (US) 2007-05-22 US disclosed
EP-1545528-A4 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC (US) 2006-07-26 EP disclosed
EP-1545528-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE SCIOS INC. (US) 2005-06-29 EP disclosed
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase SCIOS, INC. 2004-07-22 US disclosed
WO-2004022712-A2 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE SCIOS INC. (US) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142940-A1 Indole-type derivatives as inhibitors of p38 kinase MAPK1, MAPKAPK2, MAPK4 MAPK14 28/4885PRKAB2 1213/4885PRKAG1 915/4885
US-20070232617-A1 INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE MAPK1, MAPKAPK2, MAPKAPK5 MAPK14 38/4885PRKAB2 659/4885PRKAG1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.